1
|
Isu S, Vinskus L, Silva D, Cunningham K, Elich T, Greenhalgh P, Sokolnicki A, Raghunath B. Leveraging bioanalytical characterization of fractionated monoclonal antibody pools to identify aggregation-prone and less filterable proteoforms during virus filtration. Biotechnol Prog 2024:e3451. [PMID: 38450976 DOI: 10.1002/btpr.3451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 01/11/2024] [Accepted: 02/19/2024] [Indexed: 03/08/2024]
Abstract
Monoclonal antibodies (mAbs) are an essential class of biotherapeutics. A platform process is used for mAb development to ensure clinically safe and stable molecules. Regulatory authorities ensure that mAb production processes include sufficient viral clearance steps to achieve less than one virus particle per million doses of product. Virus filtration is used for size-based removal of enveloped and nonenveloped viruses during downstream processing of mAbs. Process development in mAb purification relies on empirical approaches and often includes adsorptive prefiltration to mitigate virus filter fouling. Opportunities for molecular-level prediction of mAb filterability are needed to plug the existing knowledge gap in downstream processing. A molecular-level approach to understanding the factors influencing mAb filterability may reduce process development time, material loss, and processing costs due to oversized virus filters. In this work, pH step gradient fractionation was applied on polished bulk mAb feed to obtain concentrated pools of fractionated mAb variants. Biophysical properties and quality attributes of fractionated pools, including oligomeric state (size), isoelectric point profile, diffusion interaction parameters, and glycoform profile, were determined using bioanalytical methods. Filterability (loading and throughput) of fractionated pools were evaluated. Statistical methods were used to obtain correlations between quality attributes of mAb fractions and filterability on the Viresolve Pro virus filter.
Collapse
Affiliation(s)
- Solomon Isu
- Process Solutions, MilliporeSigma, Burlington, Massachusetts, USA
| | - Lilia Vinskus
- Process Solutions, MilliporeSigma, Burlington, Massachusetts, USA
| | - Derek Silva
- Process Solutions, MilliporeSigma, Burlington, Massachusetts, USA
| | | | - Thomas Elich
- Process Solutions, MilliporeSigma, Burlington, Massachusetts, USA
| | | | - Adam Sokolnicki
- Process Solutions, MilliporeSigma, Burlington, Massachusetts, USA
| | - Bala Raghunath
- Process Solutions, MilliporeSigma, Burlington, Massachusetts, USA
| |
Collapse
|
2
|
Nitika N, Keerthiveena B, Thakur G, Rathore AS. Convolutional Neural Networks Guided Raman Spectroscopy as a Process Analytical Technology (PAT) Tool for Monitoring and Simultaneous Prediction of Monoclonal Antibody Charge Variants. Pharm Res 2024; 41:463-479. [PMID: 38366234 DOI: 10.1007/s11095-024-03663-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Accepted: 01/18/2024] [Indexed: 02/18/2024]
Abstract
BACKGROUND Charge related heterogeneities of monoclonal antibody (mAb) based therapeutic products are increasingly being considered as a critical quality attribute (CQA). They are typically estimated using analytical cation exchange chromatography (CEX), which is time consuming and not suitable for real time control. Raman spectroscopy coupled with artificial intelligence (AI) tools offers an opportunity for real time monitoring and control of charge variants. OBJECTIVE We present a process analytical technology (PAT) tool for on-line and real-time charge variant determination during process scale CEX based on Raman spectroscopy employing machine learning techniques. METHOD Raman spectra are collected from a reference library of samples with distribution of acidic, main, and basic species from 0-100% in a mAb concentration range of 0-20 g/L generated from process-scale CEX. The performance of different machine learning techniques for spectral processing is compared for predicting different charge variant species. RESULT A convolutional neural network (CNN) based model was successfully calibrated for quantification of acidic species, main species, basic species, and total protein concentration with R2 values of 0.94, 0.99, 0.96 and 0.99, respectively, and the Root Mean Squared Error (RMSE) of 0.1846, 0.1627, and 0.1029 g/L, respectively, and 0.2483 g/L for the total protein concentration. CONCLUSION We demonstrate that Raman spectroscopy combined with AI-ML frameworks can deliver rapid and accurate determination of product related impurities. This approach can be used for real time CEX pooling decisions in mAb production processes, thus enabling consistent charge variant profiles to be achieved.
Collapse
Affiliation(s)
- Nitika Nitika
- Department of Chemical Engineering, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, 110016, India
| | - B Keerthiveena
- School of Artificial Intelligence, Indian Institute of Technology Delhi, New Delhi, India
| | - Garima Thakur
- Department of Chemical Engineering, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, 110016, India
| | - Anurag S Rathore
- Department of Chemical Engineering, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, 110016, India.
- School of Artificial Intelligence, Indian Institute of Technology Delhi, New Delhi, India.
| |
Collapse
|
3
|
Anupa A, Bansode V, Kateja N, Rathore AS. A novel method for continuous chromatographic separation of monoclonal antibody charge variants by combining displacement mode chromatography and step elution. Biotechnol Prog 2024; 40:e3395. [PMID: 37828820 DOI: 10.1002/btpr.3395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Revised: 08/28/2023] [Accepted: 09/22/2023] [Indexed: 10/14/2023]
Abstract
Charge heterogeneity of monoclonal antibodies is considered a critical quality attribute and hence needs to be monitored and controlled by the manufacturer. Typically, this is accomplished via separation of charge variants on cation exchange chromatography (CEX) using a pH or conductivity based linear gradient elution. Although an effective approach, this is challenging particularly during continuous processing as creation of linear gradient during continuous processing adds to process complexity and can lead to deviations in product quality upon slightest changes in gradient formation. Moreover, the long length of elution gradient along with the required peak fractionation makes process integration difficult. In this study, we propose a novel approach for separation of charge variants during continuous CEX chromatography by utilizing a combination of displacement mode chromatography and salt-based step elution. It has been demonstrated that while the displacement mode of chromatography enables control of acidic variants ≤26% in the CEX eluate, salt-based step gradient elution manages basic charge variant ≤25% in the CEX eluate. The proposed approach has been successfully demonstrated using feed materials with varying compositions. On comparing the designed strategy with 2-column concurrent (CC) chromatography, the resin specific productivity increased by 95% and resin utilization increased by 183% with recovery of main species >99%. Further, in order to showcase the amenability of the designed CEX method in continuous operation, the method was examined in our in-house continuous mAb platform.
Collapse
Affiliation(s)
- Anupa Anupa
- School of Interdisciplinary Research, Indian Institute of Technology Delhi, New Delhi, India
| | - Vikrant Bansode
- Department of Chemical Engineering, Indian Institute of Technology Delhi, New Delhi, India
| | - Nikhil Kateja
- Department of Chemical Engineering, Indian Institute of Technology Delhi, New Delhi, India
| | - Anurag S Rathore
- Department of Chemical Engineering, Indian Institute of Technology Delhi, New Delhi, India
| |
Collapse
|
4
|
Jin X, He B. Combination of On-Line and Off-Line Two-Dimensional Liquid Chromatography-Mass Spectrometry for Comprehensive Characterization of mAb Charge Variants and Precise Instructions for Rapid Process Development. Int J Mol Sci 2023; 24:15184. [PMID: 37894864 PMCID: PMC10607358 DOI: 10.3390/ijms242015184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 10/04/2023] [Accepted: 10/12/2023] [Indexed: 10/29/2023] Open
Abstract
Charge variants, as an important quality attribute of mAbs, must be comprehensively characterized and monitored during development. However, due to their complex structure, the characterization of charge variants is challenging, labor-intensive, and time-consuming when using traditional approaches. This work combines on-line and off-line 2D-LC-MS to comprehensively characterize mAb charge variants and quickly offer precise instructions for process development. Six charge variant peaks of mAb 1 were identified using the developed platform. Off-line 2D-LC-MS analysis at the peptide level showed that the acidic peak P1 and the basic peaks P4 and P5 were caused by the deamidation of asparagine, the oxidation of methionine, and incomplete C-terminal K loss, respectively. On-line 2D-LC-MS at the intact protein level was used to identify the root causes, and it was found that the acidic peak P2 and the basic peak P6 were due to the glutathionylation of cysteine and succinimidation of aspartic acid, respectively, which were not found in off-line 2D-LC-MS because of the loss occurring during pre-treatment. These results suggest that process development could focus on cell culture for adjustment of glutathionylation. In this paper, we propose the concept of precision process development based on on-line 2D-LC-MS, which could quickly offer useful data with only 0.6 mg mAb within 6 h for precise instructions for process development. Overall, the combination of on-line and off-line 2D-LC-MS can characterize mAb charge variants more comprehensively, precisely, and quickly than other approaches. This is a very effective platform with routine operations that provides precise instructions for process development within hours, and will help to accelerate the development of innovative therapeutics.
Collapse
Affiliation(s)
- Xiaoqing Jin
- College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China;
| | - Bingfang He
- College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China;
- School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, China
| |
Collapse
|
5
|
Kumar R, Sarin D, Rathore AS. High-throughput capillary electrophoresis analysis of biopharmaceuticals utilizing sequential injections. Electrophoresis 2023; 44:767-774. [PMID: 36719057 DOI: 10.1002/elps.202200208] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Revised: 01/19/2023] [Accepted: 01/23/2023] [Indexed: 02/01/2023]
Abstract
The complexity of biotherapeutic products implies an ever-increasing list of product quality attributes that need to be monitored and characterized. In addition, the growing interest in implementing process analytical technology in biopharmaceutical production has further increased the testing burden, together with the need for rapid testing that can facilitate real-time or near-real-time decision-making. Capillary electrophoresis (CE) has made a place in biopharmaceutical analysis but is regarded as a low-throughput method, with the instrument dead time constituting more than 80% of the total time of analysis. In this study, the dead time of CE was utilized to analyse 3 mAb samples in a single-CE run. This approach resulted in an up to 77% reduction in the total analysis time and increased the productivity by up to 300%, compared to traditional single CE-ultraviolet runs, without compromising resolution or relative peak areas. Additionally, good method reproducibility was observed. The compatibility of the method has been demonstrated with protein A eluate and cation exchange chromatography fractions. We, thus, propose that sequential injections can be applied for fast and robust CE analysis of biopharmaceuticals.
Collapse
Affiliation(s)
- Ramesh Kumar
- Department of Chemical Engineering, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, India
| | - Deepika Sarin
- Department of Chemical Engineering, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, India
| | - Anurag S Rathore
- Department of Chemical Engineering, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, India
| |
Collapse
|
6
|
Ostrowski MA, Mack S, Ninonuevo M, Yan J, ElNaggar M, Gentalen E, Michels DA. Rapid multi-attribute characterization of intact bispecific antibodies by a microfluidic chip-based integrated icIEF-MS technology. Electrophoresis 2023; 44:378-386. [PMID: 36200174 PMCID: PMC10092839 DOI: 10.1002/elps.202200165] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 09/26/2022] [Accepted: 09/28/2022] [Indexed: 02/09/2023]
Abstract
Rapid, direct identification and quantitation of protein charge variants, and assessment of critical quality attributes with high sensitivity are important drivers required to accelerate the development of biotherapeutics. We describe the use of an enhanced microfluidic chip-based integrated imaged capillary isoelectric focusing-mass spectrometry (icIEF-MS) technology to assess multiple quality attributes of intact antibodies in a single run. Results demonstrate comprehensive detection of multiple charge variants of an aglycosylated knob-into-hole bispecific antibody. Upfront, on-chip separation by icIEF coupled to MS provides the orthogonal separation required to resolve and identify acidic posttranslational modifications including difficult-to-detect deamidation and glycation events at the intact protein level. In addition, on-chip UV detection enables pI determination and relative quantitation of charge isoforms. Six charge variant peaks were resolved by icIEF, mobilized toward the on-chip electrospray tip and directly identified by in-line icIEF-MS using a connected quadrupole time-of-flight mass spectrometer. In addition to acidic charge variants, basic variants were identified as C-terminal lysine, N-terminal cyclization, proline amidation, and the combination of modifications (not typically identified by other intact methods), including lysine and one or two hexose additions. Nonspecific chain cleavages were also resolved, along with their acidic charge variants, demonstrating highly sensitive and comprehensive intact antibody multi-attribute characterization within a 15-min run time.
Collapse
|
7
|
Rumanek T, Kołodziej M, Piątkowski W, Antos D. Preferential precipitation of acidic variants from monoclonal antibody pools. Biotechnol Bioeng 2023; 120:114-124. [PMID: 36226348 DOI: 10.1002/bit.28257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Revised: 09/13/2022] [Accepted: 10/08/2022] [Indexed: 11/10/2022]
Abstract
Microheterogeneity of monoclonal antibodies (mAbs) can impact their activity and stability. Formation of charge variants is considered as the most important source of the microheterogeneity. In particular, controlling the content of the acidic species is often of major importance for the production process and regulatory approval of therapeutic proteins. In this study, the preferential precipitation process was developed for reducing the content of acidic variants in mAb downstream pools. The process design was preceded by the determination of phase behavior of mAb variants in the presence of different precipitants. It was shown that the presence of polyethylene glycol (PEG) in protein solutions favored precipitation of acidic variants of mAbs. Precipitation yield was influenced by the variant composition in the mAb feed solutions, the concentration of the precipitant and the protein, and the ionic strength of the solutions. To improve yield, multistage precipitation was employed, where the precipitate was recycled to the precipitation process. The final product was a mixture of supernatants pooled together from the recycling steps. Such an approach can be potentially used either instead or in a combination with chromatography for adjusting the acidic variant content of mAbs, which can benefit in improvement in throughput and reduction in manufacturing costs.
Collapse
Affiliation(s)
- Tomasz Rumanek
- Doctoral School of Engineering and Technical Sciences at the Rzeszow University of Technology, Rzeszów, Poland
| | - Michał Kołodziej
- Department of Chemical and Process Engineering, Rzeszów University of Technology, Rzeszów, Poland
| | - Wojciech Piątkowski
- Department of Chemical and Process Engineering, Rzeszów University of Technology, Rzeszów, Poland
| | - Dorota Antos
- Department of Chemical and Process Engineering, Rzeszów University of Technology, Rzeszów, Poland
| |
Collapse
|
8
|
Abstract
IgG-based monoclonal antibody therapeutics, which are mainly IgG1, IgG2, and IgG4 subclasses or related variants, have dominated the biotherapeutics field for decades. Multiple laboratories have reported that the IgG subclasses possess different molecular characteristics that can affect their developability. For example, IgG1, the most popular IgG subclass for therapeutics, is known to have a characteristic degradation pathway related to its hinge fragility. However, there remains a paucity of studies that systematically evaluate the IgG subclasses on manufacturability and long-term stability. We thus conducted a systematic study of 12 mAbs derived from three sets of unrelated variable regions, each cloned into IgG1, an IgG1 variant with diminished effector functions, IgG2, and a stabilized IgG4 variant with further reduced FcγR interaction, to evaluate the impact of IgG subclass on manufacturability and high concentration stability in a common formulation buffer matrix. Our evaluation included Chinese hamster ovary cell productivity, host cell protein removal efficiency, N-linked glycan structure at the conserved N297 Fc position, solution appearance at high concentration, and aggregate growth, fragmentation, charge variant profile change, and post-translational modification upon thermal stress conditions or long-term storage at refrigerated temperature. Our results elucidated molecular attributes that are common to all IgG subclasses, as well as those that are unique to certain Fc domains, providing new insight into the effects of IgG subclass on antibody manufacturability and stability. These learnings can be used to enable a balanced decision on IgG subclass selection for therapeutic antibodies and aid in acceleration of their product development process.
Collapse
Affiliation(s)
- Paul Cain
- Biotechnology Discovery Research, Lilly Research Laboratories, Lilly Technology Center North, Indianapolis, IN, USA
| | - Lihua Huang
- Bioproduct Research & Development, Lilly Research Laboratories, Lilly Technology Center North, Indianapolis, IN, USA
| | - Yu Tang
- Pharmaceutical Development and Manufacturing, Syndax Pharmaceuticals, Waltham, MA, USA
| | - Victor Anguiano
- Bioproduct Research & Development, Lilly Research Laboratories, Lilly Technology Center North, Indianapolis, IN, USA
| | - Yiqing Feng
- Biotechnology Discovery Research, Lilly Research Laboratories, Lilly Technology Center North, Indianapolis, IN, USA
| |
Collapse
|
9
|
Beck A, Nowak C, Meshulam D, Reynolds K, Chen D, Pacardo DB, Nicholls SB, Carven GJ, Gu Z, Fang J, Wang D, Katiyar A, Xiang T, Liu H. Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants. Antibodies (Basel) 2022; 11:73. [PMID: 36412839 PMCID: PMC9703962 DOI: 10.3390/antib11040073] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 10/27/2022] [Accepted: 11/11/2022] [Indexed: 09/28/2023] Open
Abstract
Since the first approval of the anti-CD3 recombinant monoclonal antibody (mAb), muromonab-CD3, a mouse antibody for the prevention of transplant rejection, by the US Food and Drug Administration (FDA) in 1986, mAb therapeutics have become increasingly important to medical care. A wealth of information about mAbs regarding their structure, stability, post-translation modifications, and the relationship between modification and function has been reported. Yet, substantial resources are still required throughout development and commercialization to have appropriate control strategies to maintain consistent product quality, safety, and efficacy. A typical feature of mAbs is charge heterogeneity, which stems from a variety of modifications, including modifications that are common to many mAbs or unique to a specific molecule or process. Charge heterogeneity is highly sensitive to process changes and thus a good indicator of a robust process. It is a high-risk quality attribute that could potentially fail the specification and comparability required for batch disposition. Failure to meet product specifications or comparability can substantially affect clinical development timelines. To mitigate these risks, the general rule is to maintain a comparable charge profile when process changes are inevitably introduced during development and even after commercialization. Otherwise, new peaks or varied levels of acidic and basic species must be justified based on scientific knowledge and clinical experience for a specific molecule. Here, we summarize the current understanding of mAb charge variants and outline risk-based control strategies to support process development and ultimately commercialization.
Collapse
Affiliation(s)
- Alain Beck
- Centre d’Immunologie Pierre-Fabre (CIPF), 5 Avenue Napoléon III, 74160 Saint-Julien-en-Genevois, France
| | - Christine Nowak
- Protein Characterization, Alexion AstraZeneca Rare Disease, 100 College St., New Haven, CT 06510, USA
| | - Deborah Meshulam
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Kristina Reynolds
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - David Chen
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Dennis B. Pacardo
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Samantha B. Nicholls
- Protein Sciences, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Gregory J. Carven
- Research, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Zhenyu Gu
- Jasper Therapeutics, Inc., 2200 Bridge Pkwy Suite 102, Redwood City, CA 94065, USA
| | - Jing Fang
- Biological Drug Discovery, Biogen, 225 Binney St., Cambridge, MA 02142, USA
| | - Dongdong Wang
- Global Biologics, Takeda Pharmaceuticals, 300 Shire Way, Lexington, MA 02421, USA
| | - Amit Katiyar
- CMC Technical Operations, Magenta Therapeutics, 100 Technology Square, Cambridge, MA 02139, USA
| | - Tao Xiang
- Downstream Process and Analytical Development, Boston Institute of Biotechnology, 225 Turnpike Rd., Southborough, MA 01772, USA
| | - Hongcheng Liu
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| |
Collapse
|
10
|
Nadar S, Somasundaram B, Charry M, Billakanti J, Shave E, Baker K, Lua LHL. Design and optimization of membrane chromatography for monoclonal antibody charge variant separation. Biotechnol Prog 2022; 38:e3288. [PMID: 35818846 PMCID: PMC10078440 DOI: 10.1002/btpr.3288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Revised: 07/05/2022] [Accepted: 07/06/2022] [Indexed: 11/08/2022]
Abstract
The manufacturing scale implementation of membrane chromatography to purify monoclonal antibodies has gradually increased with the shift in industry focus towards flexible manufacturing and disposable technologies. Membrane chromatography are used to remove process-related impurities such as host cell proteins and DNA, leachates and endotoxins, with improved productivity and process flexibility. However, application of membrane chromatography to separate product-related variants such as charge variants has not gained major traction due to low binding capacity. The work reported here demonstrates that a holistic process development strategy to optimize static binding (pH and salt concentration) and dynamic process (membrane loading, flowrate, and gradient length) parameters can alleviate the capacity limitations. The study employed high throughput screening tools and scale-down membranes for intermediate and polishing purification of the model monoclonal antibody. An optimized process consisting of anion exchange and cation exchange membrane chromatography reduced the acidic variants present in Protein A eluate from 89.5 % to 19.2 % with 71 % recovery of the target protein. The membrane chromatography process also cleared host cell protein to below limit of detection with 6 to 30-fold higher membrane loading, compared to earlier reported values. The results confirm that membrane chromatography is effective in separating closely related product variants when supported by a well-defined process development strategy.
Collapse
Affiliation(s)
- Sathish Nadar
- Australian Research Council Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Corner College and Cooper Roads, Brisbane, Queensland, Australia
| | - Balaji Somasundaram
- Protein Expression Facility, The University of Queensland, Corner College and Cooper Roads, Brisbane, Queensland, Australia
| | - Marcela Charry
- Protein Expression Facility, The University of Queensland, Corner College and Cooper Roads, Brisbane, Queensland, Australia
| | - Jagan Billakanti
- Global Life Sciences Solutions Australia Pty Ltd, 32 Phillip St, Parramatta, Sydney, New south wales, Australia
| | - Evan Shave
- Australian Research Council Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Corner College and Cooper Roads, Brisbane, Queensland, Australia.,Patheon Biologics, Pharma Services Group, Thermo Fisher Scientific, 37 Kent St, Woolloongabba, Brisbane, Queensland, Australia
| | - Kym Baker
- Patheon Biologics, Pharma Services Group, Thermo Fisher Scientific, 37 Kent St, Woolloongabba, Brisbane, Queensland, Australia
| | - Linda H L Lua
- Australian Research Council Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Corner College and Cooper Roads, Brisbane, Queensland, Australia.,Protein Expression Facility, The University of Queensland, Corner College and Cooper Roads, Brisbane, Queensland, Australia
| |
Collapse
|
11
|
He X, ElNaggar M, Ostrowski MA, Guttman A, Gentalen E, Sperry J. Evaluation of an icIEF-MS system for comparable charge variant analysis of biotherapeutics with rapid peak identification by mass spectrometry. Electrophoresis 2022; 43:1215-1222. [PMID: 35286725 PMCID: PMC9322286 DOI: 10.1002/elps.202100295] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 02/02/2022] [Accepted: 02/04/2022] [Indexed: 01/27/2023]
Abstract
Protein therapeutics are usually produced in heterogeneous forms during bioproduction and bioprocessing. Heterogeneity results from post‐translational modifications that can yield charge variants and require characterization throughout product development and manufacturing. Isoelectric focusing (IEF) with UV detection is one of the most common methods to evaluate protein charge heterogeneity in the biopharmaceutical industry. To identify charge variant peaks, a new imaged microfluidic chip‐based isoelectric focusing (icIEF) system coupled directly to mass spectrometry was recently reported. Bridging is required to demonstrate comparability between existing and new technology. As such, here we demonstrate the comparability of the pI value measurement and relative charge species distributions between the icIEF‐MS system and the control data from a frequently utilized methodology in the biopharmaceutical industry for several blinded development‐phase biopharmaceutical monoclonal antibodies across a wide pI range of 7.3–9.0. Hyphenation of the icIEF system with mass spectrometry enabled direct and detailed structural determination of a test molecule, with masses suggesting acidic and basic shifts are caused by sialic acid additions and the presence of unprocessed lysine residues. In addition, MS analysis further identified several low‐abundance glycoforms. The icIEF‐MS system provides sample quantification, characterization, and identification of mAb proteoforms without sacrificing icIEF quantification comparability or speed.
Collapse
Affiliation(s)
| | | | | | - Andras Guttman
- Horvath Csaba Memorial Laboratory of Bioseparation Sciences, University of Debrecen, Hungary.,Previously with SCIEX
| | | | | |
Collapse
|
12
|
Bosley A, Cook K, Lin S, Robbins D. Improved process intermediate stability through the identification and elimination of reactive glycation residues - a monoclonal antibody case study. Bioengineered 2022; 13:14402-14412. [PMID: 35757891 PMCID: PMC9342189 DOI: 10.1080/21655979.2022.2086350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
The manufacturing of therapeutic biologics can result in a heterogeneous population of charge variants, encompassing many quality attributes which could impact activity and pharmacokinetics. Monitoring the relative abundance of these charge variants to demonstrate process consistency is an expectation of regulatory agencies. Control of the relative abundance of charge variants is also necessary to ensure product comparability across the product lifecycle. We have observed a significant shift in the relative abundance of charged species, as measured by capillary isoelectric focusing, during clarified cell culture fluid holds for several monoclonal antibodies. This lack of stability requires that the hold time for this process intermediate be significantly curtailed, eliminating manufacturing flexibility. We have identified the cause of this shift in relative abundance of charged species as changes in glycation levels, focused predominantly on three conserved, solvent accessible, lysine residues. Mutants of a model protein were generated that show increased charge state stability can be gained by eliminating these reactive lysines. Further, characterization studies were conducted on these mutants to determine the impact to biological activity and stability of the molecule, with no detrimental effects observed. Incorporating this knowledge into the assessments of candidate drugs could allow for the selection of molecules less susceptible to this product degradation pathway, allowing for greater manufacturing flexibility. This process of identifying and removing reactive lysine residues could be useful in the design of drug candidates with improved charge state stability, across a range of modalities.
Collapse
Affiliation(s)
- Allen Bosley
- Purification Process Sciences, AstraZeneca, Gaithersburg, Maryland, USA
| | - Kimberly Cook
- Antibody Discovery & Protein Engineering, AstraZeneca, Gaithersburg, Maryland, USA
| | - Shihua Lin
- Analytical Biotechnology, AstraZeneca, Gaithersburg, Maryland, USA
| | - David Robbins
- Purification Process Sciences, AstraZeneca, Gaithersburg, Maryland, USA
| |
Collapse
|
13
|
Lee AP, Kok YJ, Lakshmanan M, Leong D, Zheng L, Lim HL, Chen S, Mak SY, Ang KS, Templeton N, Salim T, Wei X, Gifford E, Tan AHM, Bi X, Ng SK, Lee DY, Ling WLW, Ho YS. Multi-omics profiling of a CHO cell culture system unravels the effect of culture pH on cell growth, antibody titer, and product quality. Biotechnol Bioeng 2021; 118:4305-4316. [PMID: 34289087 DOI: 10.1002/bit.27899] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Revised: 06/23/2021] [Accepted: 07/12/2021] [Indexed: 12/16/2022]
Abstract
A robust monoclonal antibody (mAb) bioprocess requires physiological parameters such as temperature, pH, or dissolved oxygen to be well-controlled as even small variations in them could potentially impact the final product quality. For instance, pH substantially affects N-glycosylation, protein aggregation, and charge variant profiles, as well as mAb productivity. However, relatively less is known about how pH jointly influences product quality and titer. In this study, we investigated the effect of pH on culture performance, product titer, and quality profiles by applying longitudinal multi-omics profiling, including transcriptomics, proteomics, metabolomics, and glycomics, at three different culture pH set points. The subsequent systematic analysis of multi-omics data showed that pH set points differentially regulated various intracellular pathways including intracellular vesicular trafficking, cell cycle, and apoptosis, thereby resulting in differences in specific productivity, product titer, and quality profiles. In addition, a time-dependent variation in mAb N-glycosylation profiles, independent of pH, was identified to be mainly due to the accumulation of mAb proteins in the endoplasmic reticulum disrupting cellular homeostasis over culture time. Overall, this multi-omics-based study provides an in-depth understanding of the intracellular processes in mAb-producing CHO cell line under varied pH conditions, and could serve as a baseline for enabling the quality optimization and control of mAb production.
Collapse
Affiliation(s)
- Alison P Lee
- Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Yee Jiun Kok
- Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Meiyappan Lakshmanan
- Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Dawn Leong
- Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Lu Zheng
- Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Hsueh Lee Lim
- Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Shuwen Chen
- Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Shi Ya Mak
- Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Kok Siong Ang
- Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Neil Templeton
- Process Research and Development, Merck & Co. Inc., West Point, Pennsylvania, USA
| | - Taha Salim
- Process Research and Development, Merck & Co. Inc., Kenilworth, New Jersey, USA
| | - Xiaona Wei
- Scientific Informatics, MSD International GmbH (Singapore Branch), Singapore, Singapore
| | - Eric Gifford
- Scientific Informatics, MSD International GmbH (Singapore Branch), Singapore, Singapore
| | - Andy Hee-Meng Tan
- Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Xuezhi Bi
- Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.,Duke-NUS Medical School, Singapore, Singapore
| | - Say Kong Ng
- Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Dong-Yup Lee
- Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.,School of Chemical Engineering, Sungkyunkwan University, Seoul, Gyeonggi-do, Republic of Korea
| | - Wai Lam W Ling
- Process Research and Development, Merck & Co. Inc., Kenilworth, New Jersey, USA
| | - Ying Swan Ho
- Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| |
Collapse
|
14
|
Cao L, Fabry D, Lan K. Rapid and comprehensive monoclonal antibody Characterization using microfluidic CE-MS. J Pharm Biomed Anal 2021; 204:114251. [PMID: 34265486 DOI: 10.1016/j.jpba.2021.114251] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Revised: 06/29/2021] [Accepted: 07/01/2021] [Indexed: 10/20/2022]
Abstract
The identification and control of monoclonal antibody (mAb) critical quality attributes (CQAs) is a key component of quality by design (QbD). In this work, rapid peptide mapping and native intact charge variants analysis have been developed to comprehensively characterize and monitor mAb CQAs using a microfluidic capillary electrophoresis - mass spectrometry (CE-MS) platform. The ultrafast peptide mapping simultaneously analyzed multiple CQAs, including protein primary structure, oxidation, deamidation, succinimide, C-terminal lysine (Lys) clipping, N-terminal cyclization, and glycosylation. The microfluidic CE-MS based peptide mapping acquired results comparable to conventional but lengthy liquid chromatography - MS (LC-MS) based approach. The native intact analysis resolved mAb charge variants with a comparable resolution as commonly achieved using capillary isoelectric focusing (cIEF). Charge variants' identities were assigned based on characteristic mass shifts, knowledge learned from peptide mapping, and changes in electrophoretic mobility. Major mAb glycoforms of each charge variants were resolved and identified in the deconvoluted mass spectra. Furthermore, a model simulation was performed to reconstruct intact deconvoluted mass spectra using peptide mapping results. The reconstructed and experimentally determined intact deconvoluted mass spectra were highly correlated, suggesting that our data collected at the peptide level and intact level were consistent and highly comparable. Overall, the microfluidic CE-MS based peptide mapping and native intact charge variants analysis are high-throughput methods that have great potential to support biopharmaceutical development.
Collapse
Affiliation(s)
- Li Cao
- CMC Analytical, GlaxoSmithKline, 1250 S. Collegeville Road, UP 1400, Collegeville, PA, 19426, USA.
| | - Daniel Fabry
- CMC Analytical, GlaxoSmithKline, 1250 S. Collegeville Road, UP 1400, Collegeville, PA, 19426, USA
| | - Kevin Lan
- CMC Analytical, GlaxoSmithKline, 1250 S. Collegeville Road, UP 1400, Collegeville, PA, 19426, USA
| |
Collapse
|
15
|
Gangwar N, Mishra R, Budholiya N, Rathore AS. Effect of vitamins and metal ions on productivity and charge heterogeneity of IgG1 expressed in CHO cells. Biotechnol J 2021; 16:e2000464. [PMID: 34028198 DOI: 10.1002/biot.202000464] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Revised: 03/07/2021] [Accepted: 05/19/2021] [Indexed: 12/28/2022]
Abstract
Recombinant monoclonal antibodies have emerged as the most successful modality of biotherapeutics. They are primarily expressed in Chinese Hamster Ovary (CHO) cells. It is well known that post-translational modifications (PTM) contribute significantly to heterogeneity with respect to charge, glycosylation, and size. These attributes in turn impact stability, pharmacokinetics, and pharmacodynamics of the biotherapeutic product. Cell culture media components are known to significantly contribute to both cellular productivity as well as post-translational modifications. Thus, it is highly desirable to understand how media components affect product quality. This study aims to explore the impact of vitamins and metal ions on protein expression and post-translational modifications specifically charge heterogeneity. Biotin, choline chloride, D-calcium pantothenate, folic acid, pyridoxine hydrochloride, thiamine hydrochloride vitamins and Fe, Cu, Mg, Co, Zn, Mn, Ni metal ions were examined in this study. The results indicate that pyridoxine enhances productivity while Zn, Cu, Fe, Mn, and biotin impact charge heterogeneity. While, Fe, Mn and Ni enhance production of the acidic variants, Cu and biotin inhibit it. Zn reduces formation of basic variants while biotin enhances it. The results from this investigation could be used for process control so as to get consistent charge variant profile, in particular for biosimilars.
Collapse
Affiliation(s)
- Neelesh Gangwar
- Department of Chemical Engineering, Indian Institute of Technology, New Delhi, India
| | - Rishabh Mishra
- Department of Chemical Engineering, Indian Institute of Technology, New Delhi, India
| | - Niharika Budholiya
- Department of Chemical Engineering, Indian Institute of Technology, New Delhi, India
| | - Anurag S Rathore
- Department of Chemical Engineering, Indian Institute of Technology, New Delhi, India
| |
Collapse
|
16
|
Faid V, Leblanc Y, Berger M, Seifert A, Bihoreau N, Chevreux G. C-terminal lysine clipping of IgG1: impact on binding to human FcγRIIIa and neonatal Fc receptors. Eur J Pharm Sci 2021; 159:105730. [PMID: 33493670 DOI: 10.1016/j.ejps.2021.105730] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 01/12/2021] [Accepted: 01/18/2021] [Indexed: 01/01/2023]
Abstract
Monoclonal antibodies (mAbs) display numerous structural attributes, some of them may impact their safety and/or efficacy profiles. C-terminal lysine clipping is a common phenomenon occurring during the bioproduction of mAbs and leads to variable amounts of final process-related charge variants. If Fc-glycosylation has been by far the most documented critical quality attribute (CQA), the potential impacts of mAb C-terminal lysine content is far less reported, particularly on the ability of these basic variants to bind human Fc receptors. To address this question, three charge variant species having zero (K0), one (K1) and two (K2) C-terminal lysine(s) were isolated with high purity from an in-house human IgG1 by preparative strong-cation exchange (SCX) chromatography. A comprehensive biophysical characterization of these three fractions was undertaken, demonstrating their high similarity in terms of structural homogeneity, with a particular attention paid on their respective N-glycosylation profiles. The binding affinity of the fractions to human FcγRIIIa-Val176 was assessed both by affinity chromatography and surface plasmon resonance (SPR), and to human neonatal Fc receptor (FcRn) by affinity chromatography. Results demonstrate that the three charge variants did not show any significant binding difference for the two tested human Fc receptors, translating certainly to comparable biological properties. As a consequence, C-terminal lysine clipping of the present therapeutic IgG1 should not impact both FcRn-dependent pharmacokinetic profiles and FcγRIIIa-driven cytotoxic activities. The methods used in this study can be widely applied to other IgG1 to define criticality of the C-terminal lysine clipping as a CQA.
Collapse
Affiliation(s)
- Valegh Faid
- Analytical Department, LFB Biotechnologies, 3 avenue des Tropiques, 91958 Courtaboeuf (Les Ulis), France.
| | - Yann Leblanc
- Analytical Department, LFB Biotechnologies, 3 avenue des Tropiques, 91958 Courtaboeuf (Les Ulis), France
| | - Marie Berger
- Analytical Department, LFB Biotechnologies, 3 avenue des Tropiques, 91958 Courtaboeuf (Les Ulis), France
| | - Alexander Seifert
- Analytical Department, LFB Biotechnologies, 3 avenue des Tropiques, 91958 Courtaboeuf (Les Ulis), France
| | - Nicolas Bihoreau
- Analytical Department, LFB Biotechnologies, 3 avenue des Tropiques, 91958 Courtaboeuf (Les Ulis), France
| | - Guillaume Chevreux
- Analytical Department, LFB Biotechnologies, 3 avenue des Tropiques, 91958 Courtaboeuf (Les Ulis), France
| |
Collapse
|
17
|
Abstract
When two therapeutic agents are combined in a single formulation, i.e., coformulated, the quality and safety of the individual agents must be preserved. Here we describe an approach to evaluate the quality attributes of two individual monoclonal antibodies (mAbs), designated mAb-A and mAb-B, in coformulation. The mAbs were fractionated from heat-stressed coformulated drug product (DP) by hydrophobic interaction chromatography. Each purified mAb fraction was then compared with mAb-A and mAb-B in their individual formulations from the same drug substance sources used to make the coformulated DP lot, which was subjected to the same stress conditions. Product variants were evaluated and compared by using several analytical tests, including high-performance size exclusion chromatography (HPSEC), reducing and nonreducing gel electrophoresis, ion-exchange chromatography, capillary isoelectric focusing, and peptide mapping with mass spectrometry. Intermolecular interactions in coformulated and photostressed DPs were studied by evaluating aggregates fractionated from coformulated DP by HPSEC. Aggregate fractions of coformulated DP contained dimers, but not coaggregates, of mAb-A or mAb-B. Moreover, extensive assays for higher-order structure and biological interactions confirmed that there was no interaction between the two mAb molecules in the coformulation. These results demonstrate that the two coformulated therapeutic mAbs had the same quality attributes as the individually formulated mAb-A and mAb-B, no new quality attributes were formed, and no physicochemical, intermolecular, or biological interactions occurred between the two components. The approach described here can be used to monitor the product quality of other coformulated antibodies.
Collapse
Affiliation(s)
- Jun Kim
- Analytical Sciences, Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD, USA
| | - Yoen Joo Kim
- Analytical Sciences, Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD, USA
| | - Mingyan Cao
- Analytical Sciences, Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD, USA
| | - Niluka De Mel
- Analytical Sciences, Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD, USA
| | - Methal Albarghouthi
- Analytical Sciences, Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD, USA
| | | | - Jared S Bee
- Formulation and Drug Development, REGENXBIO Inc, Rockville, MD, USA
| | - Jihong Wang
- Analytical Sciences, Viela Bio, Gaithersburg, MD, USA
| | - Xiangyang Wang
- Biopharmaceutical Development and Operations, Viela Bio, Gaithersburg, MD, USA
| |
Collapse
|
18
|
Madadkar P, Sadavarte R, Ghosh R. Performance Comparison of a Laterally-Fed Membrane Chromatography (LFMC) Device with a Commercial Resin Packed Column. Membranes (Basel) 2019; 9:E138. [PMID: 31671843 DOI: 10.3390/membranes9110138] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Revised: 10/17/2019] [Accepted: 10/24/2019] [Indexed: 11/17/2022]
Abstract
The use of conventional membrane adsorbers such as radial flow devices is largely restricted to flow-through applications, such as virus and endotoxin removal, as they fail to give acceptable resolution in bind-and-elute separations. Laterally-fed membrane chromatography or LFMC devices have been specifically developed to combine high-speed with high-resolution. In this study, an LFMC device containing a stack of strong cation exchange membranes was compared with an equivalent resin packed column. Preliminary characterization experiments showed that the LFMC device had a significantly greater number of theoretical plates per metre than the column. These devices were used to separate a ternary model protein mixture consisting of ovalbumin, conalbumin and lysozyme. The resolution obtained with the LFMC device was better than that obtained with the column. For instance, the LFMC device could resolve lysozyme dimer from lysozyme monomer, which was not possible using the column. In addition, the LFMC device could be operated at lower pressure and at significantly higher flow rates. The devices were then compared based on an application case study, i.e., preparative separation of monoclonal antibody charge variants. The LFMC device gave significantly better separation of these variants than the column.
Collapse
|
19
|
Abstract
Charge variants are important attributes of monoclonal antibodies, including antibody-drug conjugates (ADCs), because charge variants can potentially influence the stability and biological activity of these molecules. Ion exchange chromatography (IEX) is widely used for charge variants analysis of mAbs and offers the feasibility of fractionation for in-depth characterization. However, the conjugated linker-drug on ADCs could potentially affect the separation performance of IEX, considering IEX separation relies on surface charge distribution of analyte and involves the interaction between analyte surface and IEX stationary phase. Here, we investigated weak cation exchange chromatography (WCX) for its application in analyzing three ADCs (two broad distribution ADCs and an ADC with controlled conjugation sites) and the 2-drug/4-drug loaded species isolated from the two broad distribution ADCs using hydrophobic interaction chromatography. The major peaks in WCX profile were characterized via fraction collection followed by capillary electrophoresis-sodium dodecyl sulfate or peptide mapping. Results suggested that both the number of drug loads and conjugation sites could impact WCX separation of an ADC. The hypothesis was that the linker drugs could interfere with the ionic interaction between its surrounding amino acids on the mAb surface and column resin, which reduced the retention of ADCs on WCX column in this study. Our results further revealed that WCX brings good selectivity towards positional isomers, but limited resolution for different drug load, which causes the peak compositions of the two broad-distribution ADCs to be highly complex. We also compared results from WCX and imaged capillary isoelectric focusing (icIEF). Results showed that separation in icIEF was less influenced by conjugated linker drugs for the ADCs studied in this work, and better alignment was found between the two techniques for the ADC with controlled conjugate sites. Overall, this work provides insights into the complexity of WCX analysis of ADCs, which should be considered during method development and sample characterization.
Collapse
Affiliation(s)
- Zhaorui Zhang
- a Process Analytical Chemistry, AbbVie Inc. , North Chicago , IL , USA
| | - Shiyue Zhou
- a Process Analytical Chemistry, AbbVie Inc. , North Chicago , IL , USA
| | - Linjie Han
- a Process Analytical Chemistry, AbbVie Inc. , North Chicago , IL , USA
| | - Qunying Zhang
- a Process Analytical Chemistry, AbbVie Inc. , North Chicago , IL , USA
| | - Wayne A Pritts
- a Process Analytical Chemistry, AbbVie Inc. , North Chicago , IL , USA
| |
Collapse
|
20
|
Chung S, Tian J, Tan Z, Chen J, Zhang N, Huang Y, Vandermark E, Lee J, Borys M, Li ZJ. Modulating cell culture oxidative stress reduces protein glycation and acidic charge variant formation. MAbs 2019; 11:205-216. [PMID: 30602334 DOI: 10.1080/19420862.2018.1537533] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Controlling acidic charge variants is critical for an industrial bioprocess due to the potential impact on therapeutic efficacy and safety. Achieving a consistent charge variant profile at manufacturing scale remains challenging and may require substantial resources to investigate effective control strategies. This is partially due to incomplete understanding of the underlying causes for charge variant formation during the cell culture process. To address this gap, we examined the effects of four process input factors (temperature, iron concentration, feed media age, and antioxidant (rosmarinic acid) concentration) on charge variant profile. These factors were found to affect the charge profile by modulating the cell culture oxidative state. Process conditions with higher acidic peaks corresponded to elevated supernatant peroxide concentration, intracellular reactive oxygen species (ROS) levels, or both. Changes in glycation level were the primary cause of the charge heterogeneity, and for the first time, supernatant peroxide was found to positively correlate with glycation levels. Based on these findings, a novel mathematical model was developed to demonstrate that the rate of acidic species formation was exponentially proportional to the concentrations of supernatant peroxide and protein product. This work provides critical insights into charge variant formation during the cell culture process and highlights the importance of modulating of cell culture oxidative stress for charge variant control.
Collapse
Affiliation(s)
- Stanley Chung
- a Department of Chemical Engineering , Northeastern University , Boston , MA
| | - Jun Tian
- b Biologics Development, Global Product Development and Supply , Bristol-Myers Squibb Company , Devens , MA
| | - Zhijun Tan
- b Biologics Development, Global Product Development and Supply , Bristol-Myers Squibb Company , Devens , MA
| | - Jie Chen
- b Biologics Development, Global Product Development and Supply , Bristol-Myers Squibb Company , Devens , MA
| | - Na Zhang
- b Biologics Development, Global Product Development and Supply , Bristol-Myers Squibb Company , Devens , MA
| | - Yunping Huang
- c Mass Spectrometry COE 1, Global Product Development and Supply , Bristol-Myers Squibb Company , Pennington , RJ
| | - Erik Vandermark
- b Biologics Development, Global Product Development and Supply , Bristol-Myers Squibb Company , Devens , MA
| | - Jongchan Lee
- b Biologics Development, Global Product Development and Supply , Bristol-Myers Squibb Company , Devens , MA
| | - Michael Borys
- b Biologics Development, Global Product Development and Supply , Bristol-Myers Squibb Company , Devens , MA
| | - Zheng Jian Li
- b Biologics Development, Global Product Development and Supply , Bristol-Myers Squibb Company , Devens , MA
| |
Collapse
|
21
|
Vanam RP, Schneider MA, Marlow MS. Rapid quantitative analysis of monoclonal antibody heavy and light chain charge heterogeneity. MAbs 2015; 7:1118-27. [PMID: 26305772 PMCID: PMC4966340 DOI: 10.1080/19420862.2015.1085145] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2015] [Revised: 08/08/2015] [Accepted: 08/17/2015] [Indexed: 12/15/2022] Open
Abstract
An alternative method to traditional 2-dimensional gel electrophoresis (2D-PAGE) and its application in characterizing the inherent charge heterogeneity of chromatographically isolated monoclonal antibody heavy and light chains is described. This method, referred to as ChromiCE, utilizes analytical size-exclusion chromatography (SEC), performed under reducing and denaturing conditions, followed by imaged capillary isoelectric focusing (icIEF) of the chromatographically separated heavy and light chains. Under conditions suitable for the subsequent icIEF analysis, the absolute and relative SEC elution volumes of the heavy and light chains were found to be highly pH dependent, a phenomenon that can be exploited in optimizing chromatographic separation. Compared to 2D-PAGE, the ChromiCE method substantially decreases the time and labor needed to complete the analysis, improves reproducibility, and provides fully quantitative assessment of charge heterogeneity. The ChromiCE methodology was applied to a set of diverse monoclonal antibodies to demonstrate suitability for quantitative charge variant analysis of heavy and light chains. A typical application of ChromiCE in extended characterization and stability studies of a purified antibody is shown.
Collapse
Affiliation(s)
- Ram P Vanam
- Pre-Clinical Development and Protein Chemistry, Regeneron Pharmaceuticals, Inc.; Tarrytown, NY USA
| | - Michael A Schneider
- Pre-Clinical Development and Protein Chemistry, Regeneron Pharmaceuticals, Inc.; Tarrytown, NY USA
| | - Michael S Marlow
- Pre-Clinical Development and Protein Chemistry, Regeneron Pharmaceuticals, Inc.; Tarrytown, NY USA
| |
Collapse
|